TRPC3 and acute kidney injury: By pharmacologically inhibiting the ET-1 pathway and the TRPC3 signaling cascade after injury, the researchers observed a significant attenuation of pathological changes, improvement in vasoregulation, and mitigation of AKI (as depicted in   Figure 1).